ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells $1,332,400.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Chad Gassert sold 20,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $66.62, for a total value of $1,332,400.00. Following the sale, the senior vice president now owns 233,226 shares in the company, valued at approximately $15,537,516.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Chad Gassert also recently made the following trade(s):

• On Monday, April 1st, Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $67.25, for a total transaction of $1,345,000.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $67.25 on Friday. ANI Pharmaceuticals, Inc. has a 52-week low of $37.64 and a 52-week high of $70.81. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.42 billion, a PE ratio of 80.06 and a beta of 0.80. The business has a 50-day simple moving average of $66.58 and a 200-day simple moving average of $59.17.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The company had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on ANIP shares. Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price target for the company. HC Wainwright lifted their price target on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Guggenheim reissued a “buy” rating and issued a $77.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. Finally, Truist Financial raised their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $80.00.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Hussman Strategic Advisors Inc. purchased a new position in ANI Pharmaceuticals in the first quarter valued at $2,178,000. Wakefield Asset Management LLLP acquired a new position in ANI Pharmaceuticals in the 1st quarter worth about $979,000. BNP Paribas Financial Markets boosted its position in ANI Pharmaceuticals by 106.9% during the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after purchasing an additional 10,716 shares in the last quarter. Principal Financial Group Inc. grew its holdings in ANI Pharmaceuticals by 8.2% in the first quarter. Principal Financial Group Inc. now owns 87,699 shares of the specialty pharmaceutical company’s stock valued at $6,063,000 after purchasing an additional 6,626 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of ANI Pharmaceuticals by 70.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 4,033 shares of the specialty pharmaceutical company’s stock valued at $279,000 after buying an additional 1,666 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.